Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a clinical study titled ‘A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)’. The study aims to assess the effectiveness and safety of upadacitinib in adults with moderate-to-severe atopic dermatitis who have not responded adequately to dupilumab, a common treatment for this condition.
The study tests two interventions: Upadacitinib, an oral tablet, and Dupilumab, a subcutaneous injection. Upadacitinib is being evaluated for its potential to improve symptoms in patients who have not had success with Dupilumab.
This interventional study is randomized and follows a sequential intervention model without masking, focusing primarily on treatment. Participants are allocated to different treatment arms to receive either Upadacitinib or Dupilumab, with potential dose adjustments based on their response.
The study began on April 25, 2024, with a primary completion date yet to be reached. The latest update was submitted on August 19, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The outcome of this study could significantly impact AbbVie’s market position, potentially boosting its stock performance if Upadacitinib proves to be a superior treatment option. This could also affect investor sentiment positively, especially in the competitive landscape of dermatological treatments.
The study is currently ongoing, with further details available on the ClinicalTrials portal.